ALTERNATIVE TREATMENTS FOR ASTHMA - ASSESSING THE NEED

被引：12

作者：

SZEFLER, SJ

KAMADA, AK

HUGHES, D

BRENNER, AM

GELFAND, EW

机构：

[1] Ira J. and Jacqueline Neimark Laboratory of Clinical Pharmacology in Pediatrics, Department of Pediatrics, National Jewish Center for Immunology and Respiratory Medicine, University of Colorado Health Sciences Center, Denver, CO

来源：

JOURNAL OF ASTHMA | 1992年 / 29卷 / 02期

关键词：

D O I：

10.3109/02770909209059877

中图分类号：

R392 [医学免疫学];

学科分类号：

100102 ;

摘要：

Alternative treatments such as troleandomycin methotrexate, gold, and intravenous gamma globulin are sometimes considered for severe asthmatics to minimize the need for systemic corticosteroids and reduce adverse effects. These alternative therapies may also be associated with significant toxicity and expense. The ability to reduce corticosteroid use and the need for alternative treatment interventions in 125 pediatric patients at our institution were reviewed. Because corticosteroid requirements were reduced significantly, only 23 of 125 children evaluated were considered for treatment alternatives with only 10 receiving such therapy. This study emphasizes the importance of a thorough and comprehensive review of corticosteroid requirements and usage prior to initiating alternative approaches to treatment in moderate to severe asthmatics as well as in patients thought to be "steroid-dependent."

引用

页码：91 / 97

页数：7

共 20 条

[1]

Weiss K.B., Changing patterns of asthma mortality: identifying target populations at high risk, JAMA, 264, pp. 1683-1687, (1990)

[2]

Gergen P.J., Weiss K.B., Changing patterns of asthma hospitalization among children: 1979 to 1987, JAMA, 264, pp. 1688-1692, (1990)

[3]

1980–1987. Morbidity and Mortality Weekly Report, 39, pp. 493-497, (1990)

[4]

Barnes P.J., New concepts in the pathogenesis of bronchial hyperresponsiveness and asthma, J Allergy Clin Immunol, 83, pp. 1013-1026, (1989)

[5]

Wald J.A., Friedman B.F., Farr R.S., An improved protocol for using troleandomycin (TAO) in the treatment of steroid-requiring asthma, J Allergy Clin Immunol, 78, pp. 36-43, (1986)

[6]

Mullarkey M.F., Webb D.R., Pardee N.E., Methotrexate in the treatment of steroid-dependent asthma, Ann Allergy, 56, pp. 347-350, (1986)

[7]

Mullarkey M.F., Blumenstein B.A., Andrade W.P., Bailey G.A., Olason I., Wetzel C.E., Methotrexate in the treatment of corticosteroid-dependent asthma, N Engl J Med, 318, pp. 603-607, (1988)

[8]

Muranaka M., Miyamatoto T., Shida T., Kabe J., Makino S., Okumura H., Takeda K., Suzuki S., Horiuchi Y., Gold salt in the treatment of bronchial asthma-a double-blind study, Ann Allergy, 40, pp. 132-137, (1988)

[9]

Muranaka M., Nakajima K., Suzuki S., Bronchial responsiveness to acetylcholine in patients with bronchial asthma after long-term treatment with gold salt, J Allergy Clin Immunol, 67, pp. 350-356, (1981)

[10]

Bernstein D.I., Bernstein I.L., Bodenheimer S.S., Pietrusko R.G., An open study of Auranofin in the treatment of steroid-dependent asthma, J Allergy Clin Immunol, 81, pp. 6-16, (1988)

← 1 2 →